China’s National Healthcare Security Administration (NHSA) will pay one identical, tier-blind amount for 158 common ailments and procedures — from hypertension to minor surgery — whether they are treated at a top city hospital or a rural clinic, Caixin reported on Aug. 18. The reform is built to push patients into community clinics and relieve overcrowding at flagship hospitals. If your company sells medical devices, drugs, or digital health tools in China, this redraws the map of where demand — and reimbursement — will sit. Here is what it means for your China business.
Why It Matters
China pays for nearly all routine care through its basic medical insurance fund (医保, yībǎo), which means reimbursement policy is de facto market access. When the NHSA decides the same procedure gets the same payout at every hospital tier, it removes the financial reason patients historically had to crowd into tier-3 hospitals — and shifts purchasing power toward primary care.
That shift is already measurable. In Shandong province, the pilot that informed this national rollout, grassroots institutions handled more than 82% of cases for common conditions such as pneumonia and appendicitis in the first quarter of 2026. The province allocated 32.6 billion yuan (about $4.8 billion) of insurance funds to community facilities, a 20.1% increase over the pre-policy baseline, according to NHSA figures cited by Caixin.
For foreign health businesses, the message is blunt: the fastest-growing end of China’s care system is no longer the big-hospital channel where multinationals have historically concentrated their sales forces. It is the community clinic, the township health center, and the chronic-disease management path.
The Details
The reform formalizes a “primary care disease list” (基层病种, jīcéng bìngzhǒng) covering common chronic conditions and minor procedures. Under the new rules, the state fund disburses the same amount for a listed treatment no matter where it is delivered. The NHSA announced the policy on Monday, extending the tiered-diagnosis principle that China has built since 2009 (分级诊疗, fēnjí zhěnliáo) into a hard payment rule.
The policy builds on a March 2026 central government directive to skew insurance prepayments and reimbursements toward community facilities, and it feeds directly into the 15th Five-Year Plan (2026–2030), which calls for pushing “high-quality medical resources” to the community level and differentiating payment policies across hospital tiers.
| Policy step | What changed | What it means for foreign firms |
|---|---|---|
| 2009 | Tiered diagnosis system introduced | Framework only; no hard payment lever |
| March 2026 | Central guidance skews reimbursement to grassroots | First financial signal to redirect patient flow |
| Aug 18, 2026 | 158 ailments get tier-blind uniform payouts | Hard rule; community channel becomes the volume play |
| 2026–2030 | 15th Five-Year Plan pushes resources down-tier | Multi-year tailwind for primary-care products |
The friction is real, and Caixin flags it: patient skepticism persists. Many Chinese patients still believe only top hospitals offer trustworthy care, so simply equalizing payouts does not instantly move demand. Foreign suppliers that pair a lower-cost primary-care product with clinician training and clear outcome data will capture the shift faster than those that just cut prices.
For foreign device and pharma firms, this is the demand-side twin of a long-running cost-containment push. Uniform payouts squeeze margins at the top tier while building volume at the base, so the winning portfolio mixes premium hospital capital equipment with high-volume primary-care consumables and chronic-disease therapies.
What You Should Do
- Remap your channel strategy. Audit what share of your China revenue depends on tier-3 hospital purchasing. That channel will not vanish, but its growth will lag the community segment for routine care.
- Position products for primary care. Point-of-care diagnostics, chronic-disease therapies, and telemedicine tools fit the 158-ailment list better than tertiary-hospital capital equipment. See how the same demographic force is reshaping the market in our note on China’s 323 million seniors.
- Get your reimbursement codes right. Uniform payouts mean your product’s insurance code and reimbursement rate — not the hospital’s tier — now set the economics. Re-file any codes that depend on hospital grade.
- Reinforce compliance in parallel. The insurance channel is under tightening scrutiny; see Beijing’s pharma kickback crackdown before expanding any sales push.
- Watch the bulk-buying overlap. Uniform payouts interact with volume procurement. Review how brand-name drugs fare in China’s bulk-buying bids to price accordingly.
One Data Point
The number to remember: 158 — the number of common ailments and procedures now reimbursed at an identical rate across every hospital tier, a rule that redirects patient volume toward China’s community clinics.
Where to Go From Here
Based on what you just read:
- Ready to act? Read China’s 323 Million Seniors: 5 Policy Shifts Foreign Healthcare Firms Must Track
- Still comparing? See How Record 10 Brand-Name Drugs Winning China Bulk-Buying Bids Affects Foreign Pharma
- Need context? Try Beijing’s Pharma Kickback Crackdown: 5 Compliance Moves for Foreign Drugmakers
— China Gateway 360 —
Remote China market entry support, built around execution.
